Novo Nordisk logoNovo NordiskView brand email archive

Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model

Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model email from Novo Nordisk screenshot
Screenshot preview · Scroll to view the full email

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.